MANTLE CELL LYMPHOMA

This study is testing a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—for people with mantle cell lymphoma, a type of blood cancer. It aims to see if this combination is safe and effective for patients whose cancer has come back after treatment or who hav…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …

This study is testing whether a combination of two drugs, pirtobrutinib and rituximab, can provide long-term remission for people newly diagnosed with a slower-growing form of mantle cell lymphoma (MCL) without using traditional chemotherapy. It will enroll 50 adults with low or …

This study is testing whether adding the drug acalabrutinib to standard R-CHOP chemotherapy works better for people newly diagnosed with mantle cell lymphoma. The trial will enroll about 55 adults in Spain who haven't had prior cancer treatments and aren't candidates for stem cel…

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug moves through the body. Researchers will als…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This study is testing whether using MRI scans during radiation treatment can help doctors target cancer more precisely while patients receive chemotherapy. Researchers want to see if this approach is safe and practical for treating gastric and breast cancers. The study involves 7…

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This study is testing a two-part treatment for people newly diagnosed with Mantle Cell Lymphoma, a type of blood cancer. First, participants receive an intensive 6-month combination of chemotherapy and targeted drugs. Then, they receive up to two years of lower-dose 'maintenance'…

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is testing whether a new drug called rocbrutinib works better than currently approved drugs for people with mantle cell lymphoma that has come back or stopped responding to prior treatment. About 394 participants will be randomly assigned to receive either rocbrutinib …

This study is testing whether adding a pill called pirtobrutinib to a cell-based therapy (CAR T) works better for people with mantle cell lymphoma that has come back or stopped responding to treatment. The trial will enroll 60 adults to see if the combination helps patients live …

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study is testing a new combination of two drugs, nemtabrutinib and rituximab, for adults with mantle cell lymphoma who have not yet received any treatment. The goal is to see if this two-drug approach can effectively control the cancer by blocking a key protein in cancer cel…

This study is testing a new three-drug combination (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma (MCL), a type of blood cancer. It is for patients aged 65 and older, or younger adults with high-risk features. The main goals are to see if…

This early-stage study is testing a two-part treatment to prevent aggressive B-cell lymphoma from coming back after a stem cell transplant. Doctors take a patient's own immune cells, modify them to target cancer, and infuse them back. They then give a vaccine designed to boost th…

This study is testing whether combining two newer drugs, glofitamab and pirtobrutinib, is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to previous treatments. The trial will enroll about 30 adults to see if this combination can …

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing whether a combination of two oral drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma that has come back or stopped responding to other therapies. It will enroll about 30 adults whose cancer has relapsed or is refractory, including tho…

This study is testing whether combining three drugs—venetoclax, lenalidomide, and rituximab—is safe and effective for people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goals are to find the highest safe dose of the combination and to see how well …

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This is a first-in-human study to find a safe and effective dose of a new drug called ONM-501. The drug is injected directly into tumors and is being tested alone and in combination with an approved immunotherapy drug (cemiplimab) in adults with advanced cancers that have stopped…

This study is testing whether older patients with a type of blood cancer called mantle cell lymphoma can safely take breaks from their maintenance medication. Currently, patients take the drug zanubrutinib continuously, which can cause side effects and be costly. This trial will …

This study aims to understand and better manage high blood pressure and heart risks in people with certain blood cancers who are taking a specific type of medication called a BTK inhibitor. Researchers will closely monitor 100 patients for one year to see how often these side eff…

This study is testing a two-drug combination (acalabrutinib and obinutuzumab) for people with untreated, slow-growing non-Hodgkin lymphomas. The goal is to see if this approach can effectively control the cancer, improve quality of life, and determine if patients who achieve a co…

This early-stage study is testing a new drug called AZD0486, both alone and combined with other cancer treatments, for people with advanced B-cell blood cancers that have returned or stopped responding to prior therapies. It aims to find a safe dose and see if the drug can shrink…

This is a first-in-human study to test the safety of a new oral drug called SGR-1505 in adults with various types of relapsed or hard-to-treat B-cell cancers, like non-Hodgkin lymphoma and chronic lymphocytic leukemia. The main goal is to find the highest dose patients can tolera…

This study is testing if a faster, higher dose increase of a new drug called sonrotoclax is safe and tolerable for patients with certain blood cancers. It is for adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), inclu…

This study is testing a new oral medication called AS-1763 for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The trial will enroll a…

This study is testing a new combination of three drugs (glofitamab, venetoclax, and lenalidomide) for people newly diagnosed with a high-risk form of mantle cell lymphoma, a type of blood cancer. The goal is to see if this three-drug approach is safe and can keep the cancer from …

This early-stage study is testing whether collecting a patient's own blood-forming stem cells and giving them back alongside CAR-T therapy is safe and feasible for people with aggressive blood cancers that have come back or not responded to other treatments. The main goals are to…

This early-stage trial is testing a new type of cell therapy for adults with certain blood cancers that have returned or not responded to standard treatments. Doctors modify a patient's own immune cells (T cells) in a lab to better recognize and attack cancer cells, then infuse t…

This study is testing whether an oral drug called pemigatinib can help control two specific types of B-cell non-Hodgkin lymphoma that have come back or stopped responding to standard treatments. It is for adults with mantle cell lymphoma or marginal zone lymphoma who have already…

This study aims to see if adding a new drug called sonrotoclax to an existing drug (zanubrutinib) works better than zanubrutinib alone for adults whose mantle cell lymphoma has returned or stopped responding to prior treatments. It will involve about 300 participants and directly…

This study is testing a new combination of three drugs for people with mantle cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if the combination is safe and effective at putting the cancer into remission. The treatment involves taki…

This study is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—for adults who have never received treatment for mantle cell lymphoma, a type of blood cancer. The main goal is to see how many patients achieve a complete response, meaning no detectable …

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This is a first-in-human safety study testing a new personalized cell therapy called CLIC-2201. It is for adults and children with B-cell blood cancers (like leukemia and lymphoma) that have returned or not responded to other treatments. The main goal is to find the safest and mo…

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This study is testing a combination of two drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma, a type of blood cancer. The first part aims to find the safest and most effective dose. The second part will see how well this dose combination works to put the c…

This study is testing whether cancer patients prefer to receive their standard drug treatments at home instead of in a clinic. Researchers want to see if home-based care reduces the burden of travel and improves treatment satisfaction and quality of life for patients. A specializ…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study aims to monitor the long-term health of 500 patients who have already received CAR-T cell therapy for various blood cancers in earlier trials. Researchers will follow these patients for up to 15 years to check for any late-developing side effects, such as new cancers o…

This study aims to understand how certain leukemia and lymphoma drugs, called BTK inhibitors, affect the heart and may increase the risk of dangerous irregular heartbeats. Researchers will monitor 135 adults who are already taking or planning to start these drugs, using heart tes…

This study aims to understand how well lymphoma patients' immune systems respond to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 patients with various lymphoma types, comparing them over time. The goal is to learn how cancer treatments …

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…